Cancer can be broken down into four parts; mainly initiation, progression, immunosuppression, and finally metastasis, leading to death. Initiation and progression happen due to genetic reasons along with the interplay of the tumor microenvironment, whereas immunosuppression is the inefficiency of the body’s immune system to recognize and destroy cancer cells. Metastasis is the movement of tumor cells through the blood and the formation of multiple tumors into different secondary sites of the body. Metastasis is responsible for almost 90% of cancer deaths.
Unfortunately, though cancer treatment has advanced with targeted therapy and immunotherapy, there is still a huge gap as none of them addresses metastasis. One of the main reasons for these are the challenges faced in advancing a molecule targeting metastasis; from suitable In vitro models to the perfect animal model that will closely resemble the biology without alleviating cost and timelines.
Mestastop aims to provide a solution for such challenges with their unique proprietary platforms, METAssay, METSCAN, and METVivo.
Location: India, Karnataka, Bengaluru
Employees: 1-10
Total raised: $173.598K
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Mumbai Ang... | mumbaiange... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 22.10.2021 | Seed | $173.598K | Centre for... | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 20.10.2023 | Deals in brief: Employment Hero completes Series F round, Da... | Sustainability continues to pose an ongoing challenge that demands innovative solutions, and an emer... | kr-asia.co... |
| 20.10.2023 | Mestastop raised $500K Pre-Series A funding from 92 Angels, ... | Pre-Series A round led by 92 Angels and Malpani Ventures raised Rs 4.5 crore ($500k) for Mestastop S... | incubees.c... |